Abstract: Provided in the present application are an antibody against factor XIa in the activated form of coagulant factor XI, a preparation method therefor and the use thereof. The CDR of the heavy chain variable region of the antigen-binding fragment of the antibody comprises the amino acid sequence shown in SEQ ID NOs: 1-3, and the CDR of the light chain variable region thereof comprises the amino acid sequence shown in SEQ ID NOs: 4-6. The antibody can specifically bind to FXIa but not to FXI, and has the effect of inhibiting the endogenous pathway of human coagulation without affecting the exogenous pathway thereof, which can significantly inhibit the formation of arteriovenous shunt thrombosis, but does not increase the bleeding time and volume. Same has the potential to become an antithrombotic drug.

Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.

Abstract: Isolated monoclonal antibodies and antigen-binding fragments thereof are provided that specifically bind to an epitope within the serine protease domain of human MASP-2. In some embodiments, the antibodies or antigen-binding fragments thereof inhibit lectin pathway complement activation. Also provided are polynucleotides encoding the disclosed monoclonal antibodies or antigen-binding fragments thereof, and cloning vectors or expression cassettes comprising such polynucleotides. Further provided are methods of inhibiting lectin pathway complement activation and methods of treating lectin pathway diseases and disorders.

Abstract: A method of treating active Systemic Lupus Erythematosus (SLE) in a patient by administering a clinically proven safe and clinically proven effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, wherein the patient achieves a significant improvement in disease activity.

Abstract: A monoclonal antibody is provided which binds to a human CC chemokine receptor 1 (CCR1) and inhibits activation of the human CCR1, or an antibody fragment thereof. The monoclonal antibody binds to an extracellular region of a human CCR1 and inhibits activation of the human CCR1 by a human CC chemokine ligand 15 (CCL15). An antibody fragment thereof, a hybridoma producing the antibody, a nucleic acid having a nucleotide sequence encoding the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment using the hybridoma or the transformant cell; a therapeutic agent and a diagnostic agent containing the antibody or the antibody fragment, and a method for treating and diagnosing a CCR1-related disease using the antibody or the antibody fragment are also provided.

Abstract: The present disclosure discloses compositions comprising a hyaluronidase, devices comprising such compositions, as well as methods and uses employing such compositions and devices to reduce or eliminate a hyaluronic acid-induced blockage of one or more blood vessels supplying an eye of an individual; methods and uses for employing such compositions and devices to reduce or inhibit a vascular occlusion in an eye of an individual; and methods and uses for employing such compositions and devices to reduce or inhibit a hyaluronic acid-induced loss of vision of an individual.

Abstract: The present disclosure discloses compositions comprising a hyaluronidase, devices comprising such compositions, as well as methods and uses employing such compositions and devices to reduce or eliminate a hyaluronic acid-induced blockage of one or more blood vessels supplying an eye of an individual; methods and uses for employing such compositions and devices to reduce or inhibit a vascular occlusion in an eye of an individual; and methods and uses for employing such compositions and devices to reduce or inhibit a hyaluronic acid-induced loss of vision of an individual.

Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.

Abstract: Provided herewith are peptide dual agonists of at least the GIPR (glucose-dependent insulinotropic polypeptide receptor) and the GLP2R (glucagon-like peptide-2 receptor), and their use for treatment of bone disorders such as osteoporosis.

Abstract: There is provided a peptide-containing compound that comprises a peptide component which is an amino acid sequence of from 2 to 45 (e.g. from 6 to 15) amino acids, which peptide component is covalently bonded to one or more compounds of formula I: wherein: R1 is selected from the group consisting of —C(CH3)2OH, —COCH3, —C(CH3)?CH2 and —C(CH3)2H; and n is 0, 1 or 2, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide-containing compound. The compound of formula I is preferably montelukast, montelukast styrene or hydrogenated montelukast styrene. The peptide-containing compound is particularly useful in the treatment of conditions characterised by inflammation, including wounds, hemorrhoids, burns, psoriasis, acne, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, chronic obstructive pulmonary disease, inflammatory bowel disease (such as ulcerative colitis).

Abstract: Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.

Abstract: The present invention relates to the field of inflammation-associated disorders or conditions, more particularly to gut inflammation. Provided herein are means and methods to diagnose and treat or reduce the severity of inflammation-associated disorders or conditions in a subject in need thereof.

Abstract: Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a canine and methods of their use. The compositions involve variant canine IgG Fc regions.

Abstract: Targeting metastasis stem cells through a fatty acid receptor. The invention provides the use of blockers or inhibitors of CD36 activity or expression for the treatment of oral squamous cell cancer (OSCC), particularly for the treatment of generated metastases and for diminish is generation from primary tumours. Apart from shRNAs, anti-CD36 antibodies are provided as blockers or inhibitors, especially those that block the binding of CD36 to oxidized LDL and fatty acids and their incorporation into cells, because the promotion of their transport is indicated as the mechanism by which CD36 promote metastases dissemination and growth. Also provided is a method for identifying candidates to anticancer agents, particularly for OSCC metastasis, among those that promote in CD36+ cells, in vivo or in vitro, effects associated to CD36 depletion or blocking such as decrease of growth accumulation of lipid droplets and decrease of size in the case of metastases.

Abstract: Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.

Abstract: The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.

Abstract: Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.

Abstract: The present invention relates to reagent kits for in vitro measurement of YKL-40 and MASP2 and diagnosis of hepatocarcinoma of a test individual.

Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.

Abstract: In some embodiments, methods of inhibiting, ameliorating, reducing the severity of, treating, reducing the likelihood of, or preventing social isolation stress or symptoms thereof in a subject in need thereof are described. In some embodiments, methods of determining a risk of social isolation stress in a subject are described.

Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.

Abstract: The present invention provides a vaccine against IL-17A, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to SEQ ID NO: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving IL-17A as an aggravation factor, and the like.

Abstract: A method for treating an autoimmune neurological disease and/or a neurodegenerative disease is provided. The method includes administering an effective amount of at least one compound having Formula (I), Formula (II) or Formula (III), or its geometric isomer, enantiomer or diastereomer to a subject in need thereof: wherein is a single or double bond, X is NCH3 or CH2, Y is null, O or N, Z is O or N, R1 is H, OH, and R2 is null, H, C1-C8 alkyl, —(C?O)-alkyl, —(C?O)-aryl, —(C?O)-alkyl-aryl, —(C?O)-heteroaryl, cycloalkyl or heterocycloalkyl, which optionally substituted by one or more of —OH, —NO2, —NH2, —NR3R4, carbonyl, alkoxyl, alkyl or —OCF3, wherein R3 and R4 independently are H, alkyl, —SO2CH3, —(C?O)—CH3 or —(C?O)—NH2.

Abstract: The present disclosure relates to methods of treating social dysfunction neurological disorders in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity, and to a method of treating seizures in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity. In some embodiments, the compound is IFN-?.

Abstract: The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory age—iAge, the cardiovascular age—cAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.

Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.

Abstract: Disclosed herein are methods for treating subjects having rheumatoid arthritis (RA) with a human anti-interleukin 6 (IL-6) antibody, or antigen-binding portion thereof.

Abstract: Methods for preparing ex vivo T cell cultures using IL-21 compositions for use in adoptive immunotherapy are described. Addition of IL-21 to cultures of non-terminally differentiated T cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of IL-21 compositions and antigen presenting cells (APCs), the resulting T cell population has an enhanced antigen-specificity, and can be reintroduced into the patient. Methods are also disclosed for identifying tumor antigens by culturing T cell populations exposed to IL-21 compositions and APCs in the presence of tumor material.

Abstract: The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associated with motor neuron diseases are also provided.

Abstract: Methods for treating eye diseases such as dry eye disease (DED) and age-related macular degeneration (AMD) using an IL-20 antagonist that blocks the signaling pathway mediated by IL-20, for example, an antibody that binds IL-20 or an IL-20 receptor.

Abstract: The invention provides a method of treating a disease or disorder in a subject by inducing a TGF alpha immune response or by administering an anti-TGF-alpha antibody or a biologically active fragment thereof. The TGF-alpha immune response is induced using a TGF-alpha polypeptide or biologically active fragment, a vaccine, a genetic construct or a transformed cell, for example.

Abstract: Provided are a composition comprising a GAG derivative and a chemokine receptor activity regulator, and a pharmaceutical composition comprising said composition.

Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.

Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

Abstract: The present invention relates to a new formulation of the oligonucleotide of SEQ ID NO:1.

Abstract: A method of treating psoriasis in a patient previously treated with and determined to be an inadequate responder to an IL-12/23p40 antibody by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI75, PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

Abstract: The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?. Anxiety and other psychiatric conditions are also improved with this treatment.

Abstract: The present invention relates to a pharmaceutical composition for inhibiting rejection of transplanted cells including a high mobility group box 1 A domain (HMGB1A) as an active ingredient. The use of the pharmaceutical composition can minimize immunological rejection, which may occur upon cell transplantation, and increase the success rate of cell transplantation.

Abstract: A method for increasing the veracity of classification by detecting protein YKL-40 and MASP2 levels in the samples, comprises detecting the content of the YKL-40 and MASP2 in the samples; the ratio of the content of YKL-40 to the that of MASP2 acted as variable, receiving the ROC curve according to the sensitivity and specialty of the difference threshold value to the diagnosis for the cancer, calculating an area under the curve AUC; classifying the samples according to the value of the AUC, sensitivity and specialty. And a kit for detecting the protein YKL-40 and MASP2 levels in the samples.

Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

Abstract: The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.

Abstract: The present invention provides an anti-human hemoglobin monoclonal antibody or an antibody kit for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample with ease, and an insoluble carrier particle to which the monoclonal antibody is immobilized, and a measurement reagent and a measurement method for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample using the same. The anti-human hemoglobin monoclonal antibody of the present invention does not react to free hemoglobin or free haptoglobin which is not formed in a complex, but specifically reacts to a hemoglobin-haptoglobin complex when the antibody is immobilized to an insoluble carrier particle and used.

Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.

Abstract: The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, generation, or maintenance in animals.

Abstract: This document provides antibodies against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) short, and more particularly to humanized TRAILshort antibodies that can neutralize TRAILshort. For example, materials and methods for using one or more humanized TRAILshort antibodies to induce apoptosis (e.g., via TRAIL mediated cell death, natural killer (NK) cytotoxicity, and/or CD8+ T cell killing) are provided.

Abstract: The invention relates to negative functional modulators of erythropoietin (EPO) for use in the treatment of cancers, in the therapy of autoimmune -based and non-autoimmune based chronic inflammatory diseases, and in the treatment of patients under-going organ or tissue transplant, or for the treatment of hemophilic arthropathy, hemophilia A and B, von Willebrand disease, angiodysplasia, proliferative disorders and neurological diseases characterized in their pathogenesis by primary neuroinflammation and/or neuroinflammation secondary to other causes. Such modulators are anti-EPO antibodies and their derivatives: anti-EPO receptor antibodies (EPOR), antisense oligonucleotides, decoy DNA, decoy RNA, ribozyme, antagomir, shRNA, LNA and/or siRNAs that inhibit the expression of the gene encoding EPO or EPOR.

Abstract: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.